Blood Testing Market

Executive Summary

Blood Testing Market was valued at US $80.15 billion in 2021 and is projected to grow at 8.46% CAGR over the forecast period to reach US $130.44 billion by 2027. Blood Testing Market represented US $12.01 billion opportunity over 2019-2021 and estimated to create US $50.29 billion opportunity in 2027 over 2021.

Blood Testing from Consainsights analyses the Blood Testing Market in the Life Sciences industry over the forecast period to 2027.

Blood Testing research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Blood Testing segmentation includes Type, Methods, End User and Geography.

Based on the Type, the Blood Testing analysis covers Glucose Testing, Lipid Panel Testing, Prostate Specific Antigen (PSA) Testing, Blood Urea Nitrogen (BUN) Testing, Thyroid Stimulating Hormone Testing, Other Types (Direct LDL testing, Testosterone Testing).

In Type segment, Glucose Testing segment has highest cagr growth of 7.48%.

Based on the Methods, the Blood Testing analysis covers Manual Blood Testing, Automated Blood Testing.

In Methods segment, Manual Blood Testing segment has highest cagr growth of 7.48%.

Based on the End User, the Blood Testing analysis covers Diagnostic Laboratories, Hospitals, Other End Users.

In End User segment, Diagnostic Laboratories segment has highest cagr growth of 7.48%.

Based on the region, the Blood Testing analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Abbott Laboratories, Baxter International, Becton, Dickinson and Company, BioMerieux SA, BioRad Laboratories, Cepheid Corporation, Danaher Corporation, F. Hoffmann-La Roche AG, Novartis International AG, Thermo Fisher Scientific, Una Health Ltd, Shimadzu, Waters Corporation, PerkinElmer Inc. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, Glucose Testing segment has the highest revenue of US $32.50 billion and is expected to grow at CAGR of 7.48% by 2027 Glucose Testing segment has highest cagr growth of 7.48%.

Glucose Testing

Glucose Testing segment was valued at US $27.63 billion in 2019 and is projected to grow at 7.48% CAGR over the forecast period to reach US $52.90 billion by 2027. Glucose Testing segment represented US $4.87 billion opportunity over 2019-2021 and estimated to create US $20.39 billion opportunity in 2027 over 2021.

Lipid Panel Testing

Lipid Panel Testing segment was valued at US $18.39 billion in 2019 and is projected to grow at 7.48% CAGR over the forecast period to reach US $35.20 billion by 2027. Lipid Panel Testing segment represented US $3.24 billion opportunity over 2019-2021 and estimated to create US $13.57 billion opportunity in 2027 over 2021.

Prostate Specific Antigen (PSA) Testing

Prostate Specific Antigen (PSA) Testing segment was valued at US $9.19 billion in 2019 and is projected to grow at 7.48% CAGR over the forecast period to reach US $17.59 billion by 2027. Prostate Specific Antigen (PSA) Testing segment represented US $1.62 billion opportunity over 2019-2021 and estimated to create US $6.78 billion opportunity in 2027 over 2021.

Blood Urea Nitrogen (BUN) Testing

Blood Urea Nitrogen (BUN) Testing segment was valued at US $4.78 billion in 2019 and is projected to grow at 7.48% CAGR over the forecast period to reach US $9.15 billion by 2027. Blood Urea Nitrogen (BUN) Testing segment represented US $0.84 billion opportunity over 2019-2021 and estimated to create US $3.53 billion opportunity in 2027 over 2021.

Thyroid Stimulating Hormone Testing

Thyroid Stimulating Hormone Testing segment was valued at US $4.82 billion in 2019 and is projected to grow at 7.48% CAGR over the forecast period to reach US $9.23 billion by 2027. Thyroid Stimulating Hormone Testing segment represented US $0.85 billion opportunity over 2019-2021 and estimated to create US $3.56 billion opportunity in 2027 over 2021.

Other Types (Direct LDL testing, Testosterone Testing)

Other Types (Direct LDL testing, Testosterone Testing) segment was valued at US $3.32 billion in 2019 and is projected to grow at 7.48% CAGR over the forecast period to reach US $6.36 billion by 2027. Other Types (Direct LDL testing, Testosterone Testing) segment represented US $0.59 billion opportunity over 2019-2021 and estimated to create US $2.45 billion opportunity in 2027 over 2021.

Methods

Introduction

In 2021, Manual Blood Testing segment has the highest revenue of US $76.96 billion and is expected to grow at CAGR of 7.48% by 2027 Manual Blood Testing segment has highest cagr growth of 7.48%.

Manual Blood Testing

Manual Blood Testing segment was valued at US $65.43 billion in 2019 and is projected to grow at 7.48% CAGR over the forecast period to reach US $125.25 billion by 2027. Manual Blood Testing segment represented US $11.53 billion opportunity over 2019-2021 and estimated to create US $48.29 billion opportunity in 2027 over 2021.

Automated Blood Testing

Automated Blood Testing segment was valued at US $2.71 billion in 2019 and is projected to grow at 7.48% CAGR over the forecast period to reach US $5.18 billion by 2027. Automated Blood Testing segment represented US $0.48 billion opportunity over 2019-2021 and estimated to create US $2.00 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Diagnostic Laboratories segment has the highest revenue of US $34.77 billion and is expected to grow at CAGR of 7.48% by 2027 Diagnostic Laboratories segment has highest cagr growth of 7.48%.

Diagnostic Laboratories

Diagnostic Laboratories segment was valued at US $29.56 billion in 2019 and is projected to grow at 7.48% CAGR over the forecast period to reach US $56.59 billion by 2027. Diagnostic Laboratories segment represented US $5.21 billion opportunity over 2019-2021 and estimated to create US $21.82 billion opportunity in 2027 over 2021.

Hospitals

Hospitals segment was valued at US $17.17 billion in 2019 and is projected to grow at 7.48% CAGR over the forecast period to reach US $32.86 billion by 2027. Hospitals segment represented US $3.03 billion opportunity over 2019-2021 and estimated to create US $12.67 billion opportunity in 2027 over 2021.

Other End Users

Other End Users segment was valued at US $21.41 billion in 2019 and is projected to grow at 7.48% CAGR over the forecast period to reach US $40.99 billion by 2027. Other End Users segment represented US $3.77 billion opportunity over 2019-2021 and estimated to create US $15.80 billion opportunity in 2027 over 2021.